

# JOIN THE NEXT PHASE OF ESTS THYMIC RESEARCH

## THREE NEW MULTICENTER PROJECTS

**Dear Colleagues,**

Thank you for being part of our growing ESTS Thymic Working Group. With the **finalized ESTS Registry**, we now have the tools to close long-standing evidence gaps and answer key questions in thymic surgery and oncology. We are launching **three new multicenter projects** and warmly invite you **to contribute by December 1**. This is a pivotal moment: if each of our 50 members adds their cases, we can rapidly generate robust, publication-ready analyses and turn evidence into better care for our patients.

### Projects

#### 1) Role of Peri-Operative Chemotherapy in TET According to the 9th TNM

**Lead:** Marco Chiappetta

**Objective:** Evaluate the prognostic impact of peri-operative chemotherapy across the new TNM-9 T categories, comparing neoadjuvant vs adjuvant strategies and assessing resection status, with survival endpoints: Overall Survival (OS), Cancer-Specific Survival (CSS), and Disease-Free Survival (DFS).

**Variables:** TNM-9 stage (update if needed), histology, tumor size, therapy and regimen (neoadjuvant/adjuvant), R status, peri-operative complications, follow-up status and dates (OS/CSS/DFS), recurrence (date/site), and infiltrative patterns relevant to TNM-9.

#### 2) Minimally Invasive vs. Open Resection in TET - Exploring Early-Stage and Large (> 5 cm) Tumors

**Lead:** Karol Chorąży

**Objective:** Compare minimally invasive and open surgery for complications, peri-operative outcomes, OS and DFS, with special attention to early-stage and tumors > 5cm while capturing real-world trends including conversions. With markedly higher completeness in the Registry, propensity-score matching should now be feasible.

**Required variables:** Masaoka-Koga and TNM-9 stage, histology, tumor size, lymph node dissection, CT/PET-CT/SUVMax/MRI, operative approach, conversion (yes/no, reason), R status, peri-operative outcomes (complications, ICU/LOS, readmission), recurrence (date/site), and follow-up for OS/DFS.

#### 3) Evaluating the Impact of PORT (Postoperative Radiotherapy) on Thymomas and Thymic Carcinomas According to TNM-9

**Lead:** Francesco Guerrera


**Objective:** Reassess PORT using the TNM-9 framework to define its effect on Event-Free Survival (EFS) and Overall Survival (OS) and identify the stages that benefit most.

**Required variables:** Demographics, TNM-9 stage, histology, R status, PORT details, systemic therapies, recurrence (date/site), and follow-up status/dates (DFS/OS).


### How to take part

If you're interested in contributing, simply contact us and let us know which of the projects you'd like to support - participation in multiple studies is, of course, encouraged. Please ensure that your Registry data are updated to TNM-9 and include the required variables above. Authorship will follow a transparent contribution tracking system (cases, variables, data quality). We also welcome additional project ideas that align with the registry's framework.

**Thank you for your engagement, and we look forward to advancing TET together!**



**Marco Chiappetta**  
Catanzaro, Italy



**Karol Chorąży**  
Vienna, Austria



**Francesco Guerrera**  
Turin, Italy

**For collaboration, access requests, support, or additional information, please contact:**

**Bernhard Moser, MD**

**Karol Chorąży, MD**

Chair of the ESTS Thymic Working Group

Member of the ESTS Thymic Working Group

bernhard.moser@muv.ac.at

karol.chorazy@muv.ac.at

### Connect with us:

 <https://www.linkedin.com/company/ests-thymic-group>  
 <https://x.com/ESTSThymicGroup>  
 <https://www.youtube.com/@ESTSThymicGroup>